Drugs / DTaP-HB-PRP~T
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00343889 | Aug 2006 → Nov 2007 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00348881 | Jun 2006 → Oct 2007 | diphtheria, hepatitis B virus infection, influenza, pertussis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP-HB-PRP~T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00348881 ↗ |
| Modality | Vaccine | “pentavalent DTaP-HB-PRP~T vaccine” NCT00343889 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT00343889 ↗ |